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Abstract
Introduction: Nocebo effects are defined as adverse events related to negative expectations and learning processes that are
involved in the modulation of the descending pain pathways. Research over the last couple of decades has illustrated that
behavioral, psychoneurobiological, and functional changes occur during nocebo-induced pain processing.
Objectives: We aimed to review published human and nonhuman research on algesia and hyperalgesia resulting from negative
expectations and nocebo effects.
Methods: Herein, we searched and comprehensively reviewed scientific literature providing informative knowledge about the
psychoneurobiological bases of the nocebo effect in the field of pain with an emphasis on how pain processes are shaped by both
cognitive and noncognitive factors.
Results: Negative expectations are formed through verbal suggestions of heightened pain, prior nociceptive and painful
experiences, and observation of pain in others. Susceptibility to the nocebo effect can be also influenced by genetic variants,
conscious and nonconscious learning processes, personality traits, and psychological factors. Moreover, providers’ behaviors,
environmental cues and the appearance of medical devices can induce negative expectations that dramatically influence pain
perception and processing in a variety of pain modalities and patient populations.
Conclusion: Importantly, we concluded that nocebo studies outline how individual expectationsmay lead to physiological changes
underpinning the central integration and processing of magnified pain signaling. Further research is needed to develop strategies
that can identify patients with nocebo-vulnerable pain to optimize the psychosocial and therapeutic context in which the clinical
encounter occurs, with the ultimate purpose of improving clinical outcomes.
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1. Introduction
Multiple psychosocial and environmental factors encompassed
within a clinical encounter create a context through which
patients develop negative or positive expectancies about
treatments and clinical outcomes. Nocebo effects, which arise
from negative expectancies elicited through verbal suggestion,
conditioning and/or social observation,25 have the potential to
significantly influence pain pathways by triggering physiological
changes that could consequently affect not only pain perception
but also pharmacological efficacy and clinical outcomes in the
context of pain management.28 A better understanding of the
nocebo mechanisms would relevantly inform clinical practice.
Just as the multifaceted dimensions of the clinical encounter can
have a powerful therapeutic placebo analgesic effect,22,29
components of the clinical encounter can also produce algesic
and hyperalgesic nocebo effects. Following an introduction of the
nocebo effect and its methodology (eg, definition and identifica-
tion criteria), this review focuses on describing the neurobiological
changes driving this phenomenon, as well as the psychological
and cognitive factors influencing negative expectancies. Alto-
gether, these factors lead to alterations in descending pain
pathways and individual pain experiences.
Merely disclosing the potential to experience higher pain can
itself produce negative expectations and worsening of pain
outcomes. Research on the mechanisms of the nocebo effect
brings attention to multiple influencing factors within clinical
settings that are relevant for any health care provider. By
recognizing the impact of communication and interpersonal
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interactions in unsuccessful therapeutic outcomes, health care
providers may develop important strategies to mitigate nocebo
effects in the field of pain medicine. The purpose of this review is
to report published human and nonhuman research describing
neurobiological changes associated with algesia and hyper-
algesia occurring as a consequence of negative expectations and
nocebo effects.
We searched PubMed using nocebo, pain and negative
expectancy as key words. The abstracts were therefore reviewed
independently by 2 authors and the articles that were considered
most relevant for understanding the psychoneurobiological
mechanisms underpinning nocebo effects were described in
detail in this narrative review.
By collating the factors and mechanisms that have been
linked to nocebo effects, this review provides a concise
contextual framework that can guide health care practitioners,
physicians, and investigators in optimizing their interventional
strategies. By paying careful attention to an individual’s behavior
and by being aware to the wide variety of factors and
mechanisms that may influence responses to clinical interac-
tions and treatments, practitioners, and researchers can tailor
therapeutic strategies and deliver information with appropriate-
ness to reduce the risk for negative outcomes or undesired
effects.
2. Definitions and methodological considerations
The term nocebo effect was introduced in the literature to indicate
the negative counterpart of the placebo effect and to contrast the
adverse from the positive placebo effect.53,54
A “nocebo” refers to an inert substance, such as a sugar pill, as
well as to an intervention or procedure intended to create
negative expectations about health outcomes either intentionally
(eg, disclosure of side effects) or unintentionally (eg, exposure to
therapeutic encounters where a patient has experienced an
adverse event). In laboratory settings, a nocebo can refer, for
example, to the delivery of a conditioned stimulus in which a study
participant experiences higher pain along with the delivery of an
experimental noxious unconditioned stimulus. Nocebo effects
also refer to negative effects of a drug that cannot be attributed to
the pharmacokinetics of the drug (eg, reduction of expected
efficacy; negative outcome expectancies; verbal and nonverbal
negative cues in the clinical encounter). Furthermore, nocebo
effects can be induced by social interactions and observational
learning whereby study participants interact and/or observe
another person experiencing a negative outcome (eg, increased
pain) or receiving negative disclosures related to a treatment (eg,
explanation of side effects of a painkiller).
Also, it is important to distinguish the nocebo effect from the
nocebo response. As outlined by Colloca and Miller, the nocebo
effect refers to the negative psychosocial context around the
patient and the treatment as well as its neurobiological bases,32
whereas the nocebo response refers to unspecific factors that
can produce worsening of symptoms (eg, headache).
As described by Colloca and Miller,32 nocebo effects can be
either apparent or true, and accurate detection of the true
placebo effect, from a methodological perspective, requires
comparison with a no-treatment control group. For example,
when a patient reports headache as a side effect when beginning
a new medication, this headache may be in fact the result of
quality-of-life–related factors, personal distress, normal physio-
logical processes, or of the natural history of a condition, and
might have already been present prior to, or occurred regardless
of, the initiation of the new medication regimen.7,64 Thus, these
reported side effects can either be biased by misattribution, or
they could represent a true response to the nocebo effect.43
Adverse effects may be more difficult to be evaluated compared
to target outcomes because of biases related to memory effects
on retrospective symptom reporting.75,79 Moreover, the re-
searcher responsible for evaluating and reporting these side
effects and symptoms may add another level of bias by having to
subjectively attribute relevance to such reports in terms of
symptom intensity and possibility of it being drug-related.64
Altogether, these factors may cloud true nocebo effects and also
potentially affect data quality. Also, it has been described that the
methods or tools employed for measuring side effects can also
have an impact on patient nocebo effects (eg, increased pain
reports).64 These circumstances then suggest the need for
standardized assessments that would allow for between-trial
comparison of adverse effects as well as potential nocebo effects
and responses.32 As explained above, true nocebo effects can be
identified in studies which include either a no-treatment group or
a group that is not disclosed about the side effects related to
a certain treatment. Nonetheless, nondisclosed groups should
still be told about the intentional concealment of information to
prevent any potential violation of patients’ rights.32
3. Theoretical bases to understand the nocebo
phenomenon
The basic psychological mechanisms underlying the formation of
negative expectations and thus, nocebo effects, are anticipation
of and information about negative outcomes,34,76 prior lack of
therapeutic effectiveness,33,34 and observation of other patients’
pain worsening.42,60,74,77,78 A recent systematic review of 89
studies on nocebo effects found that besides from higher
negative expectancies, clear suggestions of possible symptoms
and observing others develop symptoms, higher perceived dose
of exposure is also a strong predictor of nocebo effects.80
In the following section, we describe the psychological and
psychobiological underpinnings of nocebo effects. Although
promoting placebo responses may be an intentional and desir-
able aspect of clinical practice, health care providers should avoid
producing undesirable nocebo effects. An understanding of the
psychobiological mechanisms of nocebo algesia and hyper-
algesia is of critical importancewhen evaluating aspects of clinical
care that could be impacting patients’ satisfaction with care and
overall well being.
4. Negative expectancies shaped via verbal
suggestions
Nocebo effects can result from verbal instructions or suggestions
that promote the formation of negative expectancies or the
absence of positive expectancies.
One of the earliest studies on nocebo comes from Schweiger
and Parducci, who reported a localized pain in healthy study
participants informed that an electrical current passing through
their heads could cause headache as a possible side effect.69
These findings have been recently reproduced. In a study,
participants experienced headache when going through sham
exposure to radiofrequency when in fact the radiofrequency from
the amplifier was absorbed by a load, thus suggesting that
expectations created discomfort and head pain.73
Namely, verbal instructions can also paradoxically modify the
action of drugs. Study participants who believed that they were
given a stimulant perceived an increase of their tension, despite
having taken a muscle relaxant.44 This paradoxical effect has
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also been observed with other types of medication. For
example, the typical action of 33% nitrous oxide (N2O) was
reversed from analgesia to hyperalgesia—low level of pain
perceived as higher—when healthy study participants received
misleading information about the possibility of experiencing an
increase of pain.39
Verbal suggestions are strong enough to reverse conditioned
placebo analgesia after 2 days of exposure to nonopioid
analgesic ketorolac.16 Benedetti et al showed that pain experi-
ence is highly manipulable via instructions. The authors in-
vestigated pain tolerance against ischemic arm pain after an
acquisition phase involving a verum pain-reducing medication
given along with either positive or negative verbal suggestions
(“you will receive a medication which will increase your pain” vs
“you will receive a medication which will decrease your pain”).
While the placebo procedure led to nearly the same pain
reduction as the pain medication, the nocebo information ruled
out this positive effect.16
Other studies have also revealed strong nocebo effects
induced by verbal suggestions.8,76 In the study by van Laarhoven
et al, negative verbal suggestions were designed to induce higher
expectations for itch or pain, and it was revealed that higher itch
and pain expectancies led to higher reports of both events.
Evaluation of both nocebo effects revealed stronger effects for
itch when compared to pain.8,76 Negative verbal information can
convert typically painless stimulations into painful ones and
induce nocebo responses as strong as those induced by direct
experience of negative outcomes.34,65
5. Negative expectancies shaped via conditioning
Research has shown that similarly to placebo analgesia, both
verbal suggestion and learning-conditioning paradigms can
produce nocebo hyperalgesia and allodynia, although verbal
suggestions seem to play a bigger role in the development
nocebo hyperalgesia when compared to placebo analgesia
(Figs. 1A and B).34
Although it has been documented that conditioning processes
may lead to noncognitive learning that produces placebo
responses without influencing conscious expectancies, interesting
differences between the placebo and nocebo phenomena have
been observed. For example, learning appears to influence
both the occurrence of nocebo and placebo effects; however,
the repetition of associations is less important in promoting
nocebo hyperalgesia than in consolidating placebo analge-
sia.24 Experimental evidence suggests that negative expect-
ations elicited by verbal suggestions are generally powerful
enough to produce nocebo effects of higher effect size when
compared to the placebo effect, for which it is critical to have
a first-hand experience where a positive outcome is learned
and consolidated.34,51 Nocebo responses can also derive from
prior unsuccessful experiences associated with certain med-
ications and interventions. Learned negative associations can
condition a patient to subsequently experience algesic nocebo
effects and therefore reduce the expected positive outcome of
a pain treatment. The duration of prior events marked with
exposure to pain is also relevant for the development and
perpetuation of nocebo-induced algesia.24,26,33–35 Further-
more, conditioning mechanisms appear to create more nocebo
effects in women, whereas these effects may be drivenmore by
expectations in men.56
Recently, it has been also demonstrated that nocebo effects
persist over time independently of the experimental reinforcement
procedure. In fact, both partial and continuous classical
conditioning paradigms produced nocebo effects that did not
extinguish over the entire experimental sessions.21 A different
trend has been observed for positive partial reinforcement in
which placebo effects persisted over time when established
throughout partial reinforcement, but not after continuous
reinforcement.5
Importantly, nocebo effects induced via conditioning can
occur without the conscious formation of negative expectancies.
Recent research has shown that unconscious processes
modulate placebo and nocebo effects differently.40,45,50 Evolu-
tionarily, nocebo responses and placebo responses may
represent 2 opposite pathways that coexist in the organism.
The placebo phenomenon may promote appetitive and safety
behaviors, while nocebo effects may favor perceptual mecha-
nisms that are initiated to prevent dangerous events and negative
outcomes.23
Figure 1. Verbal suggestions and conditioning elicit the same magnitude of nocebo effects. (A) Allodynic and hyperalgesic pain profiles. Allodynia refers to pain in
response to a stimulus that does not normally elicit any pain and hyperalgesia refers to increased pain from a stimulation that normally induces low pain. Adapted from
Ref. 66 (Republished with permission of The American Physiological Society, from Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev
2009;89:707–58. Permission conveyed through Copyright Clearance Center, Inc. (B) Contribution of verbal suggestions and classical conditioning to nocebo
responses. Low and high nonpainful tactile stimuli were turned into painful experiences after study participants were told about the possibility to experience high pain.
Similarly, low painwas perceived aspainful ones,with orwithout being exposed to highpain via the classical conditioning. Thus, allodynic and hyperalgesic effectsmay
be triggeredby suggestions alone. A different trendwas observed in the placebo analgesia condition inwhich experiencemattersmore thanbeing informed about pain
relief. Data from Ref. 34. The red arrow indicates the stimulation intensity. The gray arrow indicates the switch between allodynia and hyperalgesia.
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6. Negative expectancies and social learning
Nocebo effects can be the result of negative expectancies or the
failure of developing positive expectancies, and can be shaped by
social observation and vicarious learning. Pain is influenced by
social interactions and can be modulated through the observa-
tion of others.37 Observational learning is defined as changes in
behavioral patterns that are a consequence of observing the
behavior of others. Through an observation of a particular
situation, an individual acquires information about that circum-
stance and about the consequences of specific actions.6 There
are some indications about how pain-related beliefs and attitudes
are affected by the observation of others in pain.48 More
specifically, the observation of a painful experience in another
person, whether through a live or video demonstrator or
a confederate, can cause a more painful sensation in the
observer when he or she experiences the same situation.
Colloca and Benedetti26 showed that the participants who
were observing an analgesic effect in another person when a light
flashed, displayed analgesia when they were exposed to the
same light paired with high level of pain. The social observation
(vicarious learning) played an important role in the development of
placebo effects. In particular, the placebo analgesia generated in
the observer positively correlatedwith the grade of empathy of the
observer. Social learning produced placebo effects of the same
magnitude as classical conditioning.26
Similarly, vicarious learning can favor an increase of pain
experience. Yoshida et al found strong hyperalgesic effects that
were correlated with observed uncertainty following an indirect
social-observation paradigm in which participants saw a group of
8 people rate their pain levels to painful stimuli that they will later
receive on themselves. Brain imaging findings revealed that these
effects were positively correlated with periaqueductal gray
activity.82
Recently, another study sought to evaluate socially induced
nocebo hyperalgesia through a similar social-observation para-
digm.78 Ninety-seven women were exposed to either a nocebo
condition or control condition, through which participants
observed a video portraying a female model experiencing more
pain after application of an ointment in the fingers of the right or
left hand, and less pain when no ointment was applied.Women in
the nocebo condition saw the female model express high pain
when the ointment was applied, whereas those in the control
condition observed the female model report low pain throughout
the procedure. Investigators also measured multiple personality
traits and cognitive styles to evaluate the potential relationship
between these and elicitation of nocebo effects and included pain
catastrophizing, hypochondriacal concerns, and empathy, as
well as depression and anxiety as control measures. Unspecific
somatic complaints were also assessed. Results demonstrated
a significant difference in the pain ratings as an effect of group
condition, and also as an effect of ointment applications within
each condition. Women within both the nocebo and control
conditions reported more pain with application of the ointment.
Furthermore, ratings of pain were higher in the nocebo condition
than that in the control condition, which suggests a potentiated
perception of pain related to the social observation.
In this study, nocebo responses were correlated with
hypochondriacal trepidations as well as somatic complaints in
the control condition group but not in the nocebo group.78
Nonetheless, contradictory results have been observed in regard
to the psychological factors correlated with nocebo effects. In
a different study, the same research group found that the nocebo
response was positively associated with pain catastrophizing.77
The role of personality factors in the nocebo effect is further
discussed in the next section.
Another study documented that nocebo hyperalgesia was
found in a group who observed a male or female model receive
less painful stimulations with the appearance of a green-light, and
higher pain intensities with appearance of a red-light, for a period
of about 5 minutes prior to receiving the stimuli themselves.
Results showed that participants who observed the model rated
the red-stimuli as more painful when compared to the control
groupswho did not engage in the social observation period. A sex
effect was also apparent, as the hyperalgesic effects were more
potent after observing the male model receiving the painful
stimulations, regardless of the sex of the participants. Moreover,
psychological assessments revealed that empathetic traits were
a predictor of the level of nocebo hyperalgesia.74
Recently, an investigation conducted by Faasse et al showed
that social modeling influences both placebo and nocebo effects,
from a physiological and behavioral standpoint. In the study, 82
participants were administered a placebo tablet described as
a fast-acting beta-blocker which was presented as either
a branded or a generic counterpart and were told that the
purpose of the study was to evaluate the effects of themedication
on pre-examination anxiety. Following the ingestion of placebo,
groups were randomized to either see a female participant—who
was in reality a confederate—describe adverse effects related to
the ingestion of the same medication, or not. Participants were
informed that the medication would lower both their blood
pressure and heart rate, leading to greater feelings of relaxation,
and that they could experience multiple mild side effects such as
headache, tiredness, drowsiness, nausea, stomach pain, among
others. Investigators measured blood pressure, heart rate,
anxiety, and physical symptoms and found that participants in
the group exposed to the female confederate reported bothmore
total symptoms and more symptoms attributed to medication
side effects than those who were not exposed to such event.
Moreover, a significant association between sex and reported
symptoms was observed, with female participants who were
exposed to the female confederate reporting about twice as
much total number of symptoms and medication-attributed side
effects than the other groups.
Interestingly, sex-specific nocebo effects have been observed
in other social modeling and observation paradigms. Lorber et al
showed an increase in both specific and nonspecific symptoms in
participants who were randomly assigned to inhale an inert
placebo that was described as an alleged environmental toxin.
Half of the participants also observed a female confederate inhale
the supposed toxin and express specific symptoms. It was found
that following the observation of the female confederate, women
but not men reported a significant increase in specific symptoms.
In this particular study, authors were evaluating, in a laboratory
setting, the effects of expectancy and modeling in mass
psychogenic illness, which has been previously observed to
affect women more than men.59
In all the above described instances, social observational
learning stimulated both specific and nonspecific nocebo effects
and responses. This “social contagion of negative emotions”
could have strong implications in the management of individual
clinical outcomes, particularly for pain management, when
considering the interplay between the social environment as well
as the interpersonal interactions of patients.10
Social modeling through multiple media outlets, such as
medical information retrieved from the internet and shared among
social media, as well as pharmacological advertisements and
descriptions of health-related environmental factors and
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warnings through television channels are strongly involved in
socially induced nocebo effects.42 For example, Fassee et al
described the “thyroxine health scare” that affected New Zealand
following manufacturing-related modifications of Eltroxin, the
medication used in the country for thyroid replacement therapy in
patients with hypothyroidism. The drug’s size, shape, taste, and
color were different, although bioequivalence was ascertained. In
18 months, there had been a 2000-fold increase in adverse
events attributed to the medication. The reported effects, which
subsided almost completely in a year and a half, were the result of
a complex interplay of circumstances that shaped patients’
expectations and beliefs about the medication and the company
involved in its manufacture, all of which were influenced by the
following: (1) misinformation regarding the actions to be taken by
the national agency controlling medication implementation; (2)
patient’s prior negative suspicions surrounding one of the
involved companies’ financial motives and actions; (3) constant
and increased media attention and propagation of detailed
information about reported side effects across the country
through TV and radio, including false rumors alleging that the
drug’s manufacturing was taking place in India, and that
genetically modified ingredients as well as monosodium gluta-
mate were being added to the medication; (4) a health care
professional figure actively attributing side effects to the newly
implemented medication in the media; (5) changes in drug
appearance; (6) and from inaccessibility to different pharmaco-
logical agents for the same condition.41
These effects may be of special relevance in inpatient clinical
settings where patients observe other patients interacting with the
health care personnel, as well as their responses to pain and pain
treatments. Indeed, negative expectations that are induced by the
medical staff also lead to the formation of nocebo effects.15,31 In
clinical settings, expecting side effects from medical treatments is
consistently associated with higher reports of nocebo effects.
Expectations about side effects, that produce nocebo effects, can
be induced through verbal suggestion15 or written information,20
the latter including information provided during the informed
consent process about potential adverse events.7 The expect-
ations of the patients receiving a treatment are of particular
importance, but the health care provider’s belief about negative
outcomes can also produce nocebo effects. Therefore, the
relationship between patient and medical staff has the power to
influence the patient’s experience of treatment side effects.17
Additionally, failure to give positive instructions associated with
painkillers can be of utmost importance in reducing positive
expectations. In contexts where computerized pumps, which
contain pain medication and are connected directly to a patient’s
intravenous line, the patient–clinician interaction and communi-
cation is limited. In such cases, the pump is set to deliver painkillers
on demand jeopardizing the positive psychosocial context asso-
ciated with treatments. The open-hidden paradigm serves as an
empirical model for exploring the role of the psychosocial context.
Seeing, feeling, smelling, or tasting a medication tends to create
higher placebo effects. Information helps patients to direct their
attention to these features, in turn forming expectations of
effectiveness that would minimize nocebo effects.11,12,30
7. Personality factors
Factors such as choice of a medication9 and higher perceived
dose of exposure, explicit suggestions that the exposure triggers
arousal or symptoms, observing people experiencing symptoms
from the exposure, and higher expectations of symptoms have
been listed as critical variables for inducing nocebo effects
associated with medication or other interventions according to
a recent systematic review.80 In laboratory settings, recent
studies have begun to provide evidence that personality and
psychological factors are critically associated with aversive
responses to pain and proneness to nocebo effects.26 Suggest-
ibility, a trait-like characteristic facilitating body sensations (eg,
physical suggestibility), has been linked to nocebo effects.36
Catastrophizing, an important psychological factor for pain
management therapies, was also found to be relevant for nocebo
effects.77 Corsi and Colloca (under review) have recently
Figure 2. Nocebo effects persist over time. Pain reports for the context group (red) and the control group (blue). The left part shows the pain reports on a visual
analog scale from 0 (no pain) to 100 (worst pain imaginable) during 8 consecutive days of experimental testing. The same participants were tested for pain
sensitivity after 90 days and the control group showing habituation to pain but not the context group. Importantly, the fMRI data indicated a higher activation of the
right parietal operculum compared to the control group. Adapted from Ref. 65. Republished with permission of The Society for Neuroscience, from Rodriguez-
Raecke R, Doganci B, Breimhorst M, Stankewitz A, Buchel C, Birklein F, May A. Insular cortex activity is associated with effects of negative expectation on
nociceptive long-term habituation. J Neurosci 2010;30:11363–8. Permission conveyed through Copyright Clearance Center, Inc. The red marks indicate the
activation in the right pariental operculum and the red circle shows a zoomed activation area.
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demonstrated that anxiety sensitivity, physiological suggestibility,
and catastrophizing (eg, rumination, helplessness, and total
catastrophizing) are associated with nocebo hyperalgesic effects
contributing to report medium pain as an experience of harmful
intense pain. Further research is needed to explore the role of
anxiety, suggestibility, and catastrophizing on the formation of
nocebo effects. Importantly, higher expectations—belief that
something will happen or is likely to happen68—of pain were
associated with larger nocebo effects, and these effects were
independent of prior exposure to pain increases occurring as part
of the acquisition phase of a conditioning paradigm.
8. Biochemical and neurophysiological mechanisms
The behavioral studies described in the previous sections are
supported by psychopharmacological14,15 and neuroimaging
research.38,65
Neuropharmacological studies of the nocebo have detailed
some of the mechanisms underlying hyperalgesia.13,14 The oral
administration of an inert talc pill given alongwith verbal suggestions
of hyperalgesia induced an increase of cortisol plasma concen-
trations and hyperactivity of adrenocorticotropic hormone release.
Both nocebohyperalgesia andhypothalamic–pituitary–adrenal axis
(HPA) hyperactivity were blocked by the benzodiazepine diazepam,
indicating that anxiety plays a role in these effects. The mixed
cholecystokinin (CCK) type-A/B receptor antagonist, proglumide
blocked nocebo hyperalgesia with no effect on cortisol and
adrenocorticotropic hormone supporting the direct role of CCK in
the hyperalgesic nocebo effect.14 Animal studies have also showed
that the CCK antagonist CI-988 prevents anxiety-induced hyper-
algesia with an effect that was similar to that produced by the
established anxiolytic chlordiazepoxide.2
Brain imaging studies have shed light on the neuroanatomical
areas that are involved in the modulation of innocuous
stimulations,67 as well as the exacerbation of pain when study
participants expect a high-intensity noxious stimulus. Increased
anxiety and alertness lead to changes in perceptual processing,
creating an augmentation of pain experience and process-
ing.52,58,63 For example, the mere expectation to feel more pain
after the administration of an inert medication affects a laser-
induced pain experience and related laser-evoked potential
amplitude in the treated hand.62 Themagnitude of nocebo effects
were not potentiated by conditioning as occurs for the positive
placebo effects.34 Changes in EEG activity, namely, an enhance-
ment of low alpha (8–10 Hz) activity have been linked to nocebo
manipulations that increase intensity and unpleasantness of heat-
induced pain.1
Informing study participants about the occurrence of height-
ened pain, even if given only once, interferes with the natural
habituation that can be experiencedwhen painful stimulations are
repetitively delivered, and produces hyperactivity of the insular
cortex over time periods as long as 8 and even 90 days (Fig. 2).65
Expectancies also impact the interruptive function of pain that
negatively affect cognitive task performance. Positive expectation
abolished the detrimental effects of pain on cognition by changes
in functional connectivity between rostral anterior cingulate cortex
(ACC), posterior fusiform cortex and the hippocampus. Connec-
tivity between ACC and fusiform gyrus during painful stimulation
decreased in the negative expectancy group, indicating that
verbal instructions related to pain deserve further investigation.71
Startle reflex3 and electroencephalogram1 are modulated by
negative expectancies and have been associated with nocebo
hyperlagesia.
Moreover, Bingel and colleagues studied the effect of expec-
tancies (expectancy of a positive analgesic effect and expectation
of hyperalgesia or exacerbation of pain) on a fixed concentration of
the m-opioid agonist remifentanil on constant heat pain. Positive
expectancy doubled the analgesic response to remifentanil, while
expectancy of pain exacerbation blocked the remifentanil analge-
sic action. The fact that brain analgesic effects inducedbym-opioid
agonist remifentanil were completely over-ridden when study
participants were told that the drug infusion was stopped (when it
had not) indicated that negative expectations can robustly interfere
with the pharmacodynamic profile of painkillers.19 The negative
effect was mirrored by an activation of the hippocampus, an area
previously linked to the nocebo effect.57
It has been postulated that changes in cortical pain responses
may be secondary to earlier amplification of incoming pain signals
within the spinal cord. A recent study combined a conditioning
paradigm using painful contact hear stimulations with spinal
Figure 3.Nocebo effects at the level of spinal cord. Study participants were informed that a cream would increase pain experience. During the acquisition phase,
the level of pain was surreptitiously enhanced to simulate increased pain because of the cream. During the testing phase in the fMRI, the pain intensities were
identical. Participants reported higher pain to the heat stimuli delivered to a lower intensity level. The fMRI results indicated an increase of activity in the left ipsilateral
dorsal horn, suggestive of nocebo-induced hyperactivity. Adapted from Ref. 47. Republished with permission of The Society for Neuroscience, from Geuter S,
Buchel C. Facilitation of pain in the human spinal cord by nocebo treatment. J Neurosci 2013;33:13784–90. Permission conveyed through Copyright Clearance
Center, Inc. The red arrow indicates activity in the ipsilateral dorsal horn and the blue box indicates the spinal sagittal section. *p , 0.050.
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functional magnetic resonance imaging in healthy participants.
The authors detected a strong activation in the spinal cord at the
level of the stimulated dermatomesC5/C6when a local topic inert
nocebo cream was applied along with verbal suggestion of pain
increases, and with exposure to high painful stimulations during
the acquisition phase of the conditioning paradigm (Fig. 3). There
was overlapping activation in the ipsilateral dorsal horn of the
spinal cord during painful stimulations, supporting a potential
direct evidence for a pain-facilitating mechanism in the human
spinal cord in relation to nocebo effects.47
Nocebo responders showed a decrease of both mesolimbic
dopaminergic and opioid system activations. The dopaminergic
system showed reduced activity in areas of the brain such as the
ventral basal ganglia, while the endogenous opioid system
showed a reduction of activity in the rostral and subgenual
ACC, orbitofrontal cortex, anterior and posterior insulae, medial
thalamus, nucleus accumbens, amygdala, and periacqueductal
area, as evidenced in a PET study.70 Although data on the
genetics involved in the nocebo effect are limited, a recent study
by Wednt et al81 suggested a role of the Catechol-O-
Methyltransferase Val158Met Polymorphism in nocebo effects.
In this study, 62 healthy Anglo-American men were given the
immunosuppressant calcineurin inhibitor CsA during the acqui-
sition phase of a pharmacological conditioning paradigm,
followed by the placebo treatment. Results showed that those
with the Val158/Val158 genetic variant reported more general
and specific psychological andmedical complaints at baseline as
well as after medication intake, respectively. Moreover, Val158
homozygotes significantly reported more specific side effects
following placebo intake when compared to the Met158/Met158
and Val158/Met158 groups. Importantly, these results were
unrelated to treatment-related changes in psychological or
biological parameters evaluated during the experimental session
through anxiety and cardiovascular measurements. When
compared to other genotypes, Val158 homozygotes appear to
more strongly recognize naturally occurring somatovisceral
sensations and to classify them as unpleasant or noxious.81
Interestingly, Zubieta and colleagues previously observed that
Met homozygotes presented with lower pain tolerance but higher
m-opioid receptor density when compared to Val homozygotes
and heterozygotes.83 The effects of the Val158/Val158 genetic
variant of the catechol-O-methyltransferase gene on placebo
effects appear to be different than nocebo effects. A recent study
in individuals with irritable bowel syndrome showed that the
largest placebo effect occurred in met/met homozygotes.49
Although more studies with larger and more diverse samples
need to be conducted, these finding adds to the literature
describing important differences between the mechanisms of the
nocebo and placebo phenomena, and highlights catechol-O-
methyltransferase genetic variability as amediator of both nocebo
and placebo effects in an opposite fashion.
A thorough understanding of the mechanisms underlying
nocebo effects can help characterize factors driving the
interindividual variability that is distinctive of nocebo responses,
with the scope of developing personalized interventions that are
shaped based on patients’ psychophysiological characteristics.
Figure 4. Nocebo algesia and hyperalgesia are triggered by an individual’s negative expectancies around a treatment or intervention, its efficacy, and its potential
outcomes. These expectations can be shaped by verbal suggestions or instructions, the individual’s prior experience and conditioning with the same or related
treatments, as well as by the observation of others in pain (social observation/vicarious learning) and individual psychological characteristics such as personality
factors. This complex interplay of cognitive-affective factors leads to physiological changes that can initiate as well as promote algesic and hyperalgesic states
including anxiety changes along with an activation of the hypothalamic–pituitary–adrenal (HPA) axis and the cholecystokinin (CCK) system. Hypoactivity of the
mesolimbic dopaminergic and of the endogenous opioid systems have been observed following exposure to a nocebo procedure. Neurophysiological changes in
the brain include increased activity of the nCF region, the insular cortex, the hippocampus, the periaqueductal gray area (PGA), the hippocampus and the ipsilateral
dorsal horn, as well as decreased connectivity between the anterior cingulate cortex (ACC) and the fusiform gyrus. Finally, EEG recordings have also shown
increased levels of low-frequency a-waves associated with nocebo-induced pain.
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Further investigation on the genetic determinants of the
nocebo effect holds promise for developing strategies to help
identify individuals with specific genotypes and phenotypes
that could negatively influence intervention outcomes. By
doing so, clinicians could take actions that appropriately tailor
the clinical environment for the benefit of the patient. The
neurochemicals identified as influential factors in nocebo
effects, such as dopamine and CCK, partake in a variety of
complex pathways and systems associated with pain disor-
ders and its related comorbidities. Thus, knowledge on the
complexity of the endogenous pain modulation systems as
they relate to cognitive-affective factors could serve as
the foundation for understanding potential etiologies or
disease-promoting elements, as well as for developing new
intervention approaches and strategies. This way, there is
more potential for controlling interventions in both specific and
nonspecific ways to increase treatment effectiveness and
positive outcomes.
9. Conclusions
The paucity of studies linking the psychological and neurobio-
logical changes limits the transfer of knowledge from bench to
beside. It is critical to define commonalities and differences
across distinct ways to elicit nocebo effects. Exploring, for
example, how verbally induced nocebo effects differ from those
related to direct and vicarious learning can advance the overall
knowledge of this phenomenon.
Expectations deriving from the clinical encounter can produce
negative effects and outcomes. Verbal suggestions, the provider’s
behaviors, environmental conditioning cues, the appearance of
medical devices, prior experiences of failed interventions, and
social learning induce negative expectancies that are linked to the
neurobiologicalmodulation of painpathwaysandcircuitries (Fig. 4).
Additionally, affective and cognitive traits could be important as
well. Some personality traits and psychological factors, such as
anxiety,61,72 harm avoidance and persistence,36 pessimism,36,46
and fear of pain,4 may influence the responsiveness to nocebo.
Research described in this review focuses on mechanistic
findings with the scope to raise awareness about the interplay
between the changes occurring in the descending pain
modulatory systems and the individual subjective pain experi-
ence. Specifically, research on the nocebo effect indicates that
algesic and hyperalgesic effects can result from information as
well as patient–clinician communication and clinical encounters
surrounding the patient. Questions such as: How health care
providers should frame verbal and nonverbal communicationwith
their patients in light of the findings deriving from nocebo research
and howwe can accurately convey information about side effects
while minimizing nocebo effects have been discussed some-
where else18,27 and in detail in a related review specifically
designed to cover the clinical implications of nocebo research.55
These findings have the potential to help patients with chronic
pain and other comorbidities where cognitive and affective pro-
cesses act as major factors affecting pain clinical outcomes.
Nocebo research would benefit from further mechanistic studies
exploring the neural processes underlying negative changes in
somatosensory perception, nociception, and pain signaling.
Moreover, there is a critical need to explore how human behaviors
can be “deconditioned” by using psychological interventions to
reverse nocebo effects. Finally, further research on the neurobi-
ology of fear-, stress-, and anxiety-related nocebo effects can
help discover therapeutic targets to tailor the development of
pharmacological treatments.
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